Overview
Anal Dysplasia and human papillomavirus infection in HIV and HIV- men
Highlights
- 1The New England journal of medicine · 2026
- 2Journal of acquired immune deficiency syndromes (1999) · 2021
Publications
154 publications
Funding
24 grantsView NIH portfolio on RePORTER ↗
Active
9 grants- Sub-PIU54CA277834-01Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION)National Cancer Institute · 2023–2028 · via H. Lee Moffitt Cancer Center & Research Institute
- MPIUM1AI068636-15AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections, ACTG LOC: PF A5357 - Y3 Protocol Vice Chair (1560)National Institute of Allergy and Infectious Diseases · 2011–2027 · via The Regents of the University of California· 16 renewals
- KPUM1AI069419-15Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2013–2027· 2 renewals
- Sub-PIR01CA274950-02Oral HPV Research Among Latin Americans Living with HIV (ORAL) - H²National Cancer Institute · 2022–2027 · via H. Lee Moffitt Cancer Center & Research Institute
- MPIU54CA242639-06S1Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico - Supplemental ExtensionNational Cancer Institute · 2019–2027· 2 renewals
- MPIUM1CA121947-15AMC Domestic Site - Weill Cornell MedicineNational Cancer Institute · 2015–2026 · via EMMES Corporation· 6 renewals
- Co-IUM1AI164565-01REACH: Research Enterprise to Advance a Cure for HIVNational Institute of Allergy and Infectious Diseases · 2021–2026
- Co-IU01AI145921-02Immunologic control of HIV-1 through combination bNAbs and biologicsNational Institute of Allergy and Infectious Diseases · 2019–2025 · via Rockefeller University· 2 renewals
Completed grants (15)
- KPM38-CO-065-0910-4INSIGHT Flu002: An International Observational Study to Characterize Adults with InfluenzaNational Institute of Allergy and Infectious Diseases · 2009–2024 · via Institute for Clinical Research
- PIUG1CA275414-03Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)National Cancer Institute · 2022–2024
- Co-IUM1AI126617-03BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationNational Institute of Allergy and Infectious Diseases · 2018–2023
- MPIR01AG054366-05Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699National Institute on Aging · 2016–2023 · via University of California, Los Angeles· 2 renewals
- MPIU01HL123336-06A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory BiomarkersNational Heart, Lung, and Blood Institute · 2014–2023 · via The Brigham & Women's Hospital INC
- Co-ICTSC Internal Funding UL1Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1CTSC Cost Share · 2017–2022
- MPIR01DK108438-05Effect of Pitavastatin on Kidney Function in HIV-infected Persons - CRS 7804 1560 B XA868National Institute of Diabetes and Digestive and Kidney Diseases · 2016–2022 · via University of California, Los Angeles· 2 renewals
- Co-ISA 203978-01Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ TrialPatient-Centered Outcomes Research Institute · 2020–2021 · via Duke UniversityContract
- MPIR01AI123001-05Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial ParticipantsNational Institute of Allergy and Infectious Diseases · 2016–2020 · via The General Hospital Corporation (dba Massachusetts General Hospital)· 2 renewals
- KP5 U1O HA29291-02AIDS Education and Training Centers Program (AETC)Health Resources and Services Administration · 2015–2019 · via Columbia University
- Sub-PIM38-CO-065-0910-4INSIGHT 001: Strategic Timing of AntiRetroviral Treatment (START)National Institute of Allergy and Infectious Diseases · 2010–2019 · via Institute for Clinical Research
- KPUM1AI068619-11HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral TDF/FTC for PrEP in HIV-Uninfected cisMen & transWomen Who Have Sex With MenNational Institute of Allergy and Infectious Diseases · 2011–2017 · via FHI 360· 2 renewals
- MPIU01CA121947-08A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in HIV-1 Infected MenNational Cancer Institute · 2007–2015 · via University of California, Los Angeles
- MPIM01RR000047-47A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATENCRR · 2004–2007 · via NIH RePORTER
Clinical research
7 studies
Completed & closed trials (7)
- PIImpact of COVID vaccination on HIV reservoir and HIV specific immune responses among people living with HIVWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
- PIA cohort study of COVID-19-vaccinated healthcare workers to determine rate of asymptomatic SARS-CoV-2 sheddingWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
- PILiquid Biopsy Screening for HPV-associated Cancers in Persons Living with HIVWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
- PIA5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: the ACTG HIV Reservoirs Cohort (AHRC) Study_x000D_National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2022)
- PINCT04250636An Open Label, Single Arm Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals.PHASE1 · Rockefeller University · IRB STUDY CLOSURE (as of 2021)Human Immunodeficiency Virus
- PINCT02859558Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune ResponsesPHASE2 · AIDS Clinical Trial Group · IRB STUDY CLOSURE (as of 2021)HIV-1 Infection
- PINCT04334148Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)PHASE3 · Duke University · IRB STUDY CLOSURE (as of 2021)COVID-19
News mentions
4 mentionsView all WCM news ↗
- HIV Patients Fare Well with Mpox TreatmentMay 5, 2023
Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat.
- Weill Cornell Medicine Receives NIH Grant to Improve HIV-Related Cancer Care AbroadJanuary 30, 2023
Weill Cornell Medicine, Moffitt Cancer Center in Tampa, Fla., and the University of North Carolina School of Medicine have received a $3.5 million, five-year grant from the National Cancer Institute (NCI), part of the National Institutes of Health, to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
- In Brief: Treating Precancerous Anal Lesions Reduces Anal Cancer Risk by More Than Half in People with HIVJune 29, 2022
A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment.
- Mission Possible: Weill Cornell Medicine Launches an Unprecedented Research Effort in the Battle Against COVID-19March 2, 2021
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
Mentoring
1 menteeAll publications with mentees →
- COColin OgilvieMD mentee · Class of 2018
External relationships
Speaker/Lecturer
Clinical Care Options, LLC
Other
Merck Sharp & Dohme Corp · VIIV Healthcare